Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Combined ASBT Inhibitor and FGF15 Treatment Improves Therapeutic Efficacy in Experimental Nonalcoholic Steatohepatitis

Cellular and Molecular Gastroenterology and Hepatology(2021)10.1016/j.jcmgh.2021.04.013Source: DataRank Database

Combined ASBT Inhibitor and FGF15 Treatment Improves Therapeutic Efficacy in Experimental Nonalcoholic Steatohepatitis is a research paper published in Cellular and Molecular Gastroenterology and Hepatology (2021). On theSindex it has a DataRank of 0. It has been cited 43 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access43 citations

Download PDF

Cite:

Linked data & code

geo doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (10 grants)Impact (FWCI 3.72)OA: goldTopics (78)IDs (PubMed, PMC, OpenAlex)Annotations (2)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (10)

Huaiwen Wang ORCID,Wenyi Luo ORCID,Rachel R. Sharp ORCID,Cheng Chen ORCID,Lijie Gu ORCID

Live enrichment

PubMed:33965587 PMC:PMC8346663 OpenAlex:https://openalex.org/W3162051112

National Institutes of Health

Grant: 1R01 DK117965-01A1

National Institutes of Health

Grant: 1R01 DK117418

National Institutes of Health

Grant: P20GM103447

NIDDK NIH HHS

Grant: P30 DK020593

NIA NIH HHS

Grant: R21 AG065720

NIDDK NIH HHS

Grant: R01 DK117965

NIDDK NIH HHS

Grant: R24 DK090964

National Institutes of Health

Grant: 7R01DK117965-02

Regulation of Bile Acid Metabolism and Signaling in Metabolic Diseases

National Institutes of Health

Grant: 3P20GM103447-17S1

Oklahoma IDeA Network of Biomedical Research Excellence

National Institute of General Medical Sciences

FWCI

3.72

Citation Percentile

0.9%

Citation Trend

2021

2022

2023

2024

2025

2026

goldLicense: cc-by-nc-nd

journalhttps://doi.org/10.1016/j.jcmgh.2021.04.013

publisherhttps://doi.org/10.1016/j.jcmgh.2021.04.013

publisherhttps://api.elsevier.com/content/article/PII:S2352345X21000849?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S2352345X21000849?httpAccept=text/plain

repositoryhttps://pubmed.ncbi.nlm.nih.gov/33965587

Fields of Study

Liver Disease Diagnosis and TreatmentDrug Transport and Resistance MechanismsFibroblast Growth Factor Research0301 basic medicine03 medical and health sciences0303 health sciencesAnimalsBile Acids and SaltsCholesterolCombined Modality TherapyDependovirusDisease Models, AnimalFibroblast Growth FactorsFructoseGene Expression ProfilingGene Expression RegulationGenetic TherapyGenetic VectorsMaleMethylaminesMiceNon-alcoholic Fatty Liver DiseaseThiazepinesTreatment Outcome

MeSH Terms

DependovirusAnimalsBile Acids and SaltsCholesterolCombined Modality TherapyDisease Models, AnimalFibroblast Growth FactorsFructoseGene Expression RegulationGenetic VectorsMaleMethylaminesThiazepinesGenetic TherapyTreatment OutcomeGene Expression ProfilingMiceNon-alcoholic Fatty Liver Disease

Keywords

Bile acidFGF19Internal medicinePharmacologyWeight lossEndocrinologyMedicineFibroblast growth factorObesityReceptorLiver fibrosisFatty liverBile acidsCYP7A1NASHMaleThiazepinesGenetic VectorsRC799-869FructoseBile Acids and SaltsMethylaminesMiceNon-alcoholic Fatty Liver DiseaseAnimalsOriginal ResearchGene Expression ProfilingGenetic TherapyDiseases of the digestive system. GastroenterologyDependovirusCombined Modality TherapyFibroblast Growth FactorsDisease Models, AnimalCholesterolTreatment OutcomeGene Expression Regulation

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being

Combined ASBT Inhibitor and FGF15 Treatment Improves Therapeutic Efficacy in Experimental Nonalcoholic Steatohepatitis

FAIR Checklist

Authors (10)

Funding (10 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)